This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Narayana, P. A Search for Related Content PubMed PubMed Citation Articles by Narayana, P. A Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                   What's this?

Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis

University of Texas Medical School at Houston, Houston, TX, USA, ponnada.a.narayana{at}uth.tmc.edu

Jerry S Wolinsky

University of Texas Medical School at Houston, Houston, TX, USA

Sajja B Rao

University of Texas Medical School at Houston, Houston, TX, USA

Renjie He

University of Texas Medical School at Houston, Houston, TX, USA

Meghana Mehta

University of Texas Medical School at Houston, Houston, TX, USA

PROMiSe Trial MRSI Group

Multicentre baseline proton magnetic resonance spectro scopic data on primary progressive multiple sclerosis (PPMS) patients are acquired and analysed, using automatic analysis software. The metabolite ratios did not differ from centre to centre. The average N-acetylaspar tate/creatine (NA A/C r) ratio in PPMS was significantly lower compared to normal controls. No significant differences were observed in this ratio between lesion-containing regions (LC R) and normal-appearing tissues (NAT). Strong lipid resonances, even in the absence of lesions, are observed in the both grey and white matter in these patients. These observations suggest extensive diffuse and/or microscopic pathology in PPMS. No significant correlation between any of the metabolite ratios and the Extended Disability Scale Score (EDSS) or with other MR measures such as lesion burden and enhancement volumes is observed.

Key Words: MRI • N-acetylaspartate • primary progressive multiple sclerosis • proton spectroscopic imaging

Multiple Sclerosis, Vol. 10, No. 3 suppl, S73-S78 (2004)
DOI: 10.1191/1352458504ms1035oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B.R. Sajja, P.A. Narayana, J.S. Wolinsky, C.W. Ahn, and t. P. T. M. G. N/A Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study Multiple Sclerosis, January 1, 2008; 14(1): 73 - 80. [Abstract] [PDF]

				N. De Stefano, M. Filippi, D. Miller, P. J. Pouwels, A. Rovira, A. Gass, C. Enzinger, P. M. Matthews, and D. L. Arnold Guidelines for using proton MR spectroscopy in multicenter clinical MS studies Neurology, November 13, 2007; 69(20): 1942 - 1952. [Abstract] [Full Text] [PDF]